November 30, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Nuvectis Pharma, Inc. Registration Statement on Form S-1, as amended (File No. 333-260099) |
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on November 26, 2021, in which we requested acceleration of the effective date of the above-referenced Registration Statement for Tuesday, November 30, 2021, at 5:00 p.m. Eastern Time. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
Please feel free to contact Matt Mamak of Alston & Bird LLP, legal counsel to the Company, at (212) 210-1256 or via email at matthew.mamak@alston.com if you have any questions.
| Nuvectis Pharma, Inc. | ||
| By: | /s/ Ron Bentsur | |
| Name: Ron Bentsur | ||
| Title: Chairman, President, and Chief Executive Officer | ||